Aspira Women's Health Reports Flat Q3 Revenue and Higher Gross Margin
Aspira Women's Health reported Q3 2025 product revenues of $2.3 million, flat compared to Q3 2024. The average unit price per test rose by 7% year-over-year, and gross profit margin improved by 5.7%. The company is advancing R&D, focusing on its ENDOinform™ program and expanding OvaSuite™ technology in major IDNs for ovarian cancer risk assessment. Aspira aims to strengthen ties with large healthcare systems and IDNs.
Aspira Women’s Health Inc. reported total product revenues of $2.3 million for the third quarter of 2025, remaining relatively flat compared to the same period in 2024. The company noted a 7.0% year-over-year increase in the average unit price per test for its commercial product portfolio, which includes Ova1Plus™ and OvaWatch℠. Gross profit margin improved by 5.7% year-over-year, attributed to higher sales productivity and disciplined expense management. Aspira continues to advance its research and development efforts, particularly with its ENDOinform™ program, and has implemented its OvaSuite™ technology in a major Integrated Delivery Network (IDN) to assist with ovarian cancer risk assessment. The company’s strategic focus remains on expanding relationships with large healthcare systems and IDNs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women’s Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102380) on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
